ClinicalTrials.gg
RecruitingNCT06361940MAPPERUpdated Oct 20, 2026

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

A Phase 2 interventional study of Aromatase inhibitors or tamoxifen in Breast Cancer, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Medical College of Wisconsin · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Updated Oct 20, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Breast Neoplasms by Medical College of Wisconsin — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · Medical College of Wisconsin.

Planned enrollment
4th of 17
185 · median 45
Started
2024
with 2 others
Phase 2
4 of 23
2 open now
Primary completion
2028-09
later than 8 of 10 live
Registered
18th of 23
by date

Among the 23 studies in Breast Neoplasms by Medical College of Wisconsin, this one is the 4th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 18th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 23 studies in Breast Neoplasms by Medical College of Wisconsin are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Breast Neoplasms by Medical College of Wisconsin, or all of them as a file.
02

Study summary

This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).

Read the detailed description

Patients with HR+ HER2- node-negative breast cancers generally undergo surgical resection upfront, followed by adjuvant chemotherapy, if needed, in addition to adjuvant endocrine therapy. Because endocrine therapy is primarily delivered in the postoperative setting, the ability to assess the tumor response to this treatment modality is lost and very difficult to assess. This study offers the unique opportunity to assess the responsiveness of breast tumors to endocrine therapy while the tumors are still in vivo by treating patients with endocrine therapy before surgery and assessing molecular changes with treatment. By comparing pre- and post-treatment levels of molecular markers with advanced omic analysis in individual tumors, the investigators expect to identify predictors of responsiveness to existing agents and identify new candidate therapeutic targets.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • hormone receptor-positive
  • HER2-negative
  • endocrine therapy
  • neoadjuvant
  • anastrozole
  • letrozole
  • exemestane
  • tamoxifen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unilateral diagnostic breast mammogram and ultrasound within 60 days of enrollment.
  2. proven diagnosis of invasive breast cancer, clinical stage I or II.
  3. Patients must be clinically lymph node negative. Lymph node negativity must be confirmed by clinical exam and/or ultrasound imaging.
  4. The patient must be female.
  5. Age ≥18 years.
  6. Estrogen and/or progesterone receptor positive tumor defined ≥1% positively staining cells by immunohistochemistry, according to the current American Society of Clinical Oncology/College of American Pathologists guidelines.
  7. Human epidermal growth factor receptor 2 () /neu must be negative by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).
  8. (ECOG) performance status 0 to 2.
  9. Bilateral breast cancer and/or multifocal, multicentric disease is allowed.
  10. Appropriate pretreatment evaluations for protocol entry, including no clinical evidence for distant , based upon the following minimum diagnostic workup: history/physical examination, including breast exam (inspection and palpation of the breasts), clinically negative axillary lymph nodes, within 28 days prior to study entry.
  11. The patient must qualify for endocrine treatment (treatment of choice), per the treating medical oncologist.
  12. The patient must provide study-specific prior to study entry.
  13. Patients with a prior history of breast cancer will be considered eligible, if they have completed all treatment (including endocrine therapy) more than two years prior to registration.
  14. Patients must not have had a prior treatment for this breast cancer or for any diagnosed or treated within the past two years, with the exception of non-melanomatous skin cancer, carcinoma in situ of the cervix.
  15. Women of childbearing age will be advised to use adequate methods of . Adequate methods of contraception for premenopausal women include barrier methods and/or non-hormonal methods (Intrauterine devices etc.).
  16. Strong cytochrome P450 2D6 (CYP2D6) inhibitors will be prohibited with tamoxifen, as it can decrease the efficacy of tamoxifen. There are no known strong interactions with aromatase inhibitors.

Exclusion criteria

Exclusion Criteria:

  1. American Joint Committee on Cancer (AJCC) clinical T4, N1-3 or M1, breast cancer.
  2. Synchronous non-breast (exceptions include non-melanomatous skin cancer, carcinoma in situ of the cervix).
  3. Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ).
  4. Men with breast cancer. Male breast cancer is a rare event and it is unclear if endocrine treatment approach is safe in men.
  5. Medical, psychiatric or other condition that would prevent the patient from receiving the protocol therapy or providing .
  6. Pregnant or lactating women are ineligible.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
185 participants (estimated)

Study arms

  • Experimental
    Standard-of-care Endocrine therapy

    Once enrolled, patients would be treated with the current standard-of-care endocrine therapy.

    Drug: Aromatase inhibitors or tamoxifen

Interventions

  • DrugAromatase inhibitors or tamoxifen

    Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the number of subjects with increased HER-1 receptor tyrosine kinases protein expression in tumors.

    Pathologists will use immunohistochemistry (IHC) to determine the average count of tumor protein expression. IHC is reported categorically as 0,1, 2 or 3. Any increase between these categories is considered increase.

    Time frame: Time of surgery

  2. Change from baseline in the number of subjects with increased HER-2 receptor tyrosine kinases protein expression in tumors.

    Pathologists will use immunohistochemistry to determine the average count of tumor protein expression. IHC is reported categorically as 0,1,2 or 3. Any increase between these categories is considered increase.

    Time frame: Time of surgery

  3. Change from baseline in the number of subjects with increased HER-3 receptor tyrosine kinases protein expression in tumors.

    Pathologists will use immunohistochemistry to determine the average count of tumor protein expression. IHC is reported categorically as 0,1,2 or 3. Any increase between these categories is considered increase.

    Time frame: Time of surgery

  4. Change from baseline in the number of subjects with increased HER-4 receptor tyrosine kinases protein expression in tumors.

    Pathologists will use immunohistochemistry to determine the average count of tumor protein expression. IHC is reported categorically as 0,1,2 or 3. Any increase between these categories is considered increase.

    Time frame: Time of surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2028, 48 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 48 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2028 → Sep 2028 and completion Dec 2029 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 12, 2024
StartActual
Sep 30, 2024
Primary completionEst.
Sep 2028was Dec 2028
CompletionEst.
Dec 2028was Dec 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2028→Sep 2028
Oct 20, 2026
Study completion
Dec 2029→Dec 2028
Oct 20, 2026
Enrollment
100→185
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Dec 2028→Sep 2028
    Study completion Dec 2029→Dec 2028
    Enrollment 100→185
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06361940
Responsible party
Lubna Chaudhary (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Apr 12, 2024
Start date
Sep 30, 2024
Primary completion
Sep 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Medical College of Wisconsin Cancer Center Clinical Trials Office
Contact
cccto@mcw.edu
866-680-0505 ext. 8900
Lubna N Chaudhary, MD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Exemestane

Start the discussion